US EditionEverest Medicines Announces FDA Clearance of IND Application for Tumor-Associated Antigen Vaccine EVM14
- EVM14 received U.S. FDA clearance for its Investigational New Drug application, marking Everest's first internally discovered program and the first mRNA therapeutic cancer vaccine approved for global clinical development.
- EVM14 is designed to treat various cancers, including non-small cell lung cancer and head and neck cancer, targeting multiple tumor-associated antigens.
- Everest Medicines plans to submit the IND application for EVM14 to the China National Medical Products Administration in the near future.
- The company highlighted that EVM14 represents a critical breakthrough in their mRNA technology strategy, aiming to provide new treatment options for cancer patients.
Insights by Ground AI
Does this summary seem wrong?
32 Articles
32 Articles
All
Left
3
Center
8
Right
3
Everest Medicines Announces FDA Clearance of IND Application for Tumor-Associated Antigen Vaccine EVM14
EVM14 received U.S. FDA clearance for its IND application, becoming Everest's first internally discovered program, and the first mRNA therapeutic cancer vaccine to be cleared for global clinical development.Preclinical highlights：EVM14 induced a dose-dependent, antigen-specific immune response in mice and significantly…
·Pennsylvania, United States
Read Full Article
Coverage Details
Total News Sources32
Leaning Left3Leaning Right3Center8Last UpdatedBias Distribution57% Center
Bias Distribution
- 57% of the sources are Center
57% Center
L 21%
C 57%
R 21%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
